Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)

    ... donors (MUD) produces similar survival for patients with acute myelogenous leukemia . Whether these results can be extended to patients ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Reduced ribosomal RNA expression and increased ribosomal DNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes

    ... for patients with MDS, increasing time to progression to acute myelogenous leukemia and improving overall response rates. Although ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older male and in ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Myelodysplastic syndromes: the role of the immune system in pathogenesis

    ... risk of infection, and variable risk of progression to acute myelogenous leukemia . Several theories of MDS pathogenesis exist, with ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older male and in ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

    ... blood cytopenias and a marked propensity to progress to acute myelogenous leukemia . With 40,000-76,000 new cases per year in the USA, ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Safety and efficacy of azacitidine in myelodysplastic syndromes.

    ... in overall survival and delaying time to progression to acute myelogenous leukemia . The recommended dosage of azacitidine is 75 mg/m(2) ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. The myelodysplastic syndrome as a prototypical epigenetic disease.

    ... balance and result in the development of acute myelogenous leukemia . Although MDS is clinically and physiologically heterogeneous, a ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

    ... (AAK) inhibitor. In this phase 2 trial, 57 patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome received alisertib ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Types

    ... case of MDS? How likely is your case to become AML ( acute myelogenous leukemia )? How long are you likely to live? ...

    Topic section last updated 07/20/2018 - 5:15pm.